SCHEMBL321669

SCHEMBL321669

COc1c(-c2ccccc2)c(C(=O)c2ccc3[nH]c(=O)n(CC(=O)O)c(=O)c3c2)n2ccccc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ MAPK8 P45983 2/20 0.39
▸ KMT2A Q03164 5/20 0.38
▸ MAPT P10636 5/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ ALDH1A1 P00352 5/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ GAA P10253 3/20 0.36
▸ GLA P06280 1/20 0.36
▸ HPGD P15428 2/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ TUBB4A P04350 1/20 0.35
▸ TUBB P07437 1/20 0.35
▸ TUBA3C P0DPH7 1/20 0.35
▸ TUBA1B P68363 1/20 0.35
▸ TUBA4A P68366 1/20 0.35
▸ TUBB4B P68371 1/20 0.35
▸ TUBB3 Q13509 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31160912 0.92 HDAC1 (0.39) HDAC1HDAC6MAPK8KMT2AMAPT
SCHEMBL31160996 0.92 HDAC1 (0.38) HDAC1HDAC6MAPK8KMT2AMAPT
SCHEMBL14916426 0.90 MAPT (0.39) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL31161028 0.90 TSPO (0.39) HDAC1HDAC6MAPK8KMT2AMAPT
SCHEMBL16340821 0.81 HTT (0.39) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL31161039 0.81 SMN1; SMN2 (0.36) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL15067731 0.80 MAPT (0.35) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL15067410 0.80 MAPT (0.35) MAPTSMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL14917190 0.80 NPC1 (0.40) KMT2AMAPTMEN1SMN1; SMN2ALDH1A1
SCHEMBL15067756 0.79 MCL1 (0.35) KMT2AMAPTSMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP claimed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US claimed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP claimed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US claimed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO claimed
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 — — EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 HDAC1 1225/4885HDAC6 1344/4885MAPK8 1910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback